TY - JOUR
T1 - Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer
AU - Nomura, H.
AU - Tsuda, H.
AU - Kataoka, F.
AU - Chiyoda, T.
AU - Yamagami, W.
AU - Tominaga, E.
AU - Susumu, N.
AU - Aoki, D.
PY - 2012
Y1 - 2012
N2 - Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.
AB - Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.
KW - Irinotecan
KW - Liposomal doxorubicin
KW - Ovarian cancer
KW - Platinum-resistant
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=84860609385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860609385&partnerID=8YFLogxK
M3 - Article
C2 - 22439412
AN - SCOPUS:84860609385
SN - 0392-2936
VL - 33
SP - 86
EP - 89
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
IS - 1
ER -